High-dose intravenous anakinra treatment is safe and effective in severe and critical COVID-19 patients: a propensity score-matched study in a single center.

Murat BektasServet YüceMustafa AyMuhammed Hamdi UyarMustafa Erkut OnderMuhammed İkbal Kılıç

Published in: Inflammopharmacology (2023)

In our study, mortality was lower in patients receiving anakinra compared to SoC. Intravenous high-dose anakinra is safe and effective treatment in patients with severe and critical COVID-19.

Keyphrases

high dose
sars cov
low dose
stem cell transplantation
early onset
type diabetes
risk factors
cardiovascular events
respiratory syndrome coronavirus